A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-beta-1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers.

Trial Profile

A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-beta-1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Mibenratide (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 08 Jan 2010 New trial record
    • 05 Jan 2010 Trial status changed from ongoing to completed based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top